The evolving landscape of immunotherapy in solid tumors.

Area of Science:

• Oncology
• Immunology
• Cancer Therapy

Background:

• Traditional cancer treatments include surgery, local therapies, and chemotherapy.
• Cancer immunotherapy has emerged as a crucial addition and alternative to conventional treatments.

Purpose of the Study:

• To review the efficacy of programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte associated protein 4 (CTLA-4) blockade.
• To discuss biomarkers predicting response to immunotherapy.
• To highlight novel therapeutic targets in late-stage clinical trials and strategies for overcoming therapy resistance.

Main Methods:

• Literature review of early immunotherapy successes.
• Analysis of biomarkers for therapeutic response.
• Overview of ongoing Phase III trials for novel targets and combination therapies.
• Discussion of innovations for treatment-resistant cancers.

Main Results:

• Programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte associated protein 4 (CTLA-4) blockade have shown significant early success.
• Biomarkers are crucial for identifying patients likely to respond to immunotherapy.
• Novel targets are being investigated in Phase III trials, both alone and with PD-1 inhibitors.

Conclusions:

• Immunotherapy is a cornerstone of modern cancer treatment, complementing or replacing traditional methods.
• Understanding biomarkers and exploring novel targets are key to improving patient outcomes.
• Innovations are needed to address challenges in therapy-resistant solid tumors.